China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Trump Buys SpaceX Shares After Record IPO 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Tesla Raises Cybertruck Prices by $5,000 in US 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Add as a preferred source on Google
Irvine, CA, May 03, 2018 -- TRIMEDYNE, INC. (OTCPINK “TMED”) today reported its financial results for its quarter ending on March 31, 2018.
For the quarter ended March 31, 2018, Trimedyne had revenues of $1,352,000, an increase of 21% from revenues of $1,119,000 for the prior year quarter. We had a net income for the current quarter of $24,000 or $0.20 per share, as compared to a net loss of $31,000 or $(0.25) per share for the prior year quarter. The net income during the current quarter as compared to a net loss during the prior year quarter is a considerable improvement, which was primarily the result of an increase of export sales revenue and the continuation of our cost controls.
For the six-month period ended March 31, 2018, Trimedyne had revenues of $2,886,000, an increase of 30% from revenues of $2,213,000 for the prior year six-month period. We had net income for the current six-month period of $110,000 or $0.90 per share, as compared to a net loss of $256,000 or $(2.09) per share for the prior year six-month period. The net income during the current six-month period as compared to a net loss during the prior year six-month period is a considerable improvement, which was primarily the result of an increase of export sales revenue and the continuation of our cost controls.
Commenting on the financial results for the quarter, Marvin P. Loeb, Sc.D., Chairman of Trimedyne, said: “Since we are no longer required to file periodic reports with the SEC, our Financial Statements are un-audited. However, we believe our Financial Statements have been prepared and contain all adjustments of a recurring nature that are necessary for a fair presentation of our operations and financial condition for the periods and dates shown.”
“We appreciate the patience of our shareholders, and we are working hard to improve our financial condition.”
If you would like a copy of the financial statements, please send an email to [email protected], and we will be happy to send it to you.
CONTACT: Jeffrey Rudner (949) 951-3800, Ext. 285 [email protected]
